Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Behav Anal Pract ; 15(4): 1170-1183, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36605160

ABSTRACT

In the practice of applied behavior analysis (ABA) treatment, implicit bias, which can be defined in behavioral terms, needs to be addressed because it may inadvertently lead to overt forms of discrimination on the basis of race. Although little research has been conducted within the field of ABA on racial implicit bias, information gathered from related fields can provide insight as to how behavior analysts can promote positive change in this area. Drawing from existing literature, recommendations are provided regarding assessment and administration of interventions to reduce racial implicit bias for clinicians. The purpose of this article is to provide strategies that behavior analysts can implement to assess and reduce behaviors related to implicit bias exhibited by practitioners, thereby reducing racial discrimination with clients and staff.

2.
Oncotarget ; 7(41): 67373-67386, 2016 Oct 11.
Article in English | MEDLINE | ID: mdl-27634913

ABSTRACT

MRP1 transporter correlates positively with glioma malignancy and the Multiple Drug Resistance (MDR) phenotype in Glioblastoma Multiforme (GBM). Evidence shows that the MRP1 transporter is controlled by the adenosine signalling axis. The aim of this study was to identify the role of adenosine on the MDR phenotype in Glioblastoma Stem-like Cells (GSCs), the cell population responsible for the tumorigenic and chemoresistance capabilities of this tumour. We found that GSCs have increased intrinsic capacity to generate extracellular adenosine, thus controlling MRP1 transporter expression and activity via activation of the adenosine A3 receptor (A3AR). We showed PI3K/Akt and MEK/ERK1/2 signaling pathways downstream A3AR to control MRP1 in GSCs. In vitro pharmacological blockade of A3AR had a chemosensitizing effect, enhancing the actions of antitumour drugs and decreasing cell viability and proliferation of GSCs. In addition, we produced an in vivo xenograft model by subcutaneous inoculation of human GSCs in NOD/SCID-IL2Rg null mice. Pharmacological blockade of A3AR generated a chemosensitizing effect, enhancing the effectiveness of the MRP1 transporter substrate, vincristine, reducing tumour size and the levels of CD44 and Nestin stem cell markers as well as the Ki-67 proliferation indicator. In conclusion, we demonstrated the chemosensitizing effect of A3AR blockade on GSCs.


Subject(s)
Brain Neoplasms/pathology , Drug Resistance, Neoplasm/physiology , Glioblastoma/pathology , Multidrug Resistance-Associated Proteins/metabolism , Neoplastic Stem Cells/pathology , Receptor, Adenosine A3/metabolism , Animals , Brain Neoplasms/metabolism , Glioblastoma/metabolism , Heterografts , Humans , Mice , Mice, Inbred NOD , Mice, SCID , Neoplastic Stem Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL